Biomonitoring data provide evidence of exposure of environmental chemicals but are not, by themselves, direct measures of exposure. To use biomonitoring data in understanding exposure, physiologically based pharmacokinetic (PBPK) modeling can be used in a reverse dosimetry approach to assess a distribution of exposures possibly associated with specific blood or urine levels of compounds. Reverse dosimetry integrates PBPK modeling with exposure pattern characterization, Monte Carlo analysis, and statistical tools to estimate a distribution of exposures that are consistent with biomonitoring data in a population. The present study used an existing PBPK model for chloroform as a generic framework to develop PBPK models for other trihalomethanes (THMs). Using Monte Carlo sampling techniques, probabilistic information about pharmacokinetics and exposure patterns was included to estimate distributions of THMs concentrations in blood in relation to various exposure patterns in a diverse population. In addition, the possibility of inhibition of hepatic metabolism among THMs was evaluated under the scenarios of household exposure. These studies demonstrated how PBPK modeling can be used as a tool to estimate a population distribution of exposures that could have resulted in particular biomonitoring results. When toxicity level is known, this tool can also be used to estimate proportion of population above levels associated with health risk.
Introduction
Physiologically based pharmacokinetic (PBPK) modeling integrates knowledge of physiology and biochemistry to describe the biological processes that regulate chemical uptake, distribution, metabolism, and elimination. Owing to their ability to support extrapolations from high-to-low exposures, between species, and across routes and timeframes of exposures, PBPK models have been developed for a large variety of volatile and nonvolatile compounds. In conventional usage, PBPK models estimate internal doses based on known external exposures. This process will be referred to here as ''forward dosimetry''. Together with toxicity and mechanistic studies, forward dosimetry can be used to define the dose-response relationship based on effective tissue dose, rather than administered dose, in risk assessment.
Despite its well-accepted role as an analytical tool for improving the scientific basis of risk assessment procedures, the use of PBPK modeling has been applied only recently in estimating human exposures or health risks from biomonitoring data (Georgopoulos et al., 1994; Roy et al., 1996; Clewell et al., 1999; Sohn et al., 2004; Aylward et al., 2005; Stern, 2005; Gosselin et al., 2006) . Biomonitoring data collected and reported in recent years are valuable for several roles: (1) establishing baseline measures of human exposure to environmental chemicals, (2) identifying subgroups with higher exposures, (3) tracking trends in exposure levels, and (4) setting priorities for research on human health effects (CDC, 2005) . However, the interpretation of biomonitoring data to evaluate human health risk remains a challenging task. For example, out of the 148 chemicals sampled by CDC in the Third National Report on Human Exposure to Environmental Chemicals, only 25 chemicals have established toxicity values (e.g., reference doses (RfD's), Minimal Risk Levels, or cancer potency values). Of those, only five have established Biological Exposure Indices (BEIs) that allow direct interpretation of measured concentrations of biomarkers (CDC, 2005) . When only exposure-based toxicity values are available, health risk can be estimated only when the relationship between biomarkers and exposures can be determined. Such relationships can be established using PBPK modeling.
The current study evaluates the application of PBPK modeling in conjunction with Monte Carlo sampling technique and probabilistic information to generate distributions of exposures to trihalomethanes (THMs) that would be consistent with THMs concentrations measured in blood.
In contrast to forward dosimetry, we refer to this process as ''reverse dosimetry'', which integrates PBPK modeling with exposure pattern characterization, Monte Carlo analysis, and statistical tools to estimate a distribution of exposures that are consistent with the biomonitoring data measured in a population.
The THMs consist of chloroform, bromodichloromethane (BDCM), dibromochloromethane (DBCM), and bromoform (TBM). These compounds are often referred to as disinfection byproducts as they are one of the groups of compounds formed as a result of the reaction of chlorine disinfectants with organic matter in water. Concerns regarding widespread exposures to THMs from the use of contaminated drinking water have led to numerous studies on THMs, including epidemiological studies, exposure assessments, mechanistic and toxicity studies, and risk assessments Wallace, 1997; Constan et al., 1999; Luciene da Silva et al., 1999; Backer et al., 2000; Corley et al., 2000; Kerger et al., 2000; Nieuwenhuijsen et al., 2000; Poulin and Theil, 2000; Allis and Zhao, 2002; Levesque et al., 2002; Gordon et al., 2006) . Owing to its greater abundance in drinking water, the most-studied compound among the four THMs is chloroform. In previous work, we have demonstrated the application of PBPK modeling in reverse dosimetry for the case of chloroform (Tan et al., 2006 ). In the current study, the reverse dosimetry approach is extended to the other THMs.
For chloroform and BDCM, CYP2E1 is the principal catalyst of their oxidative metabolism (Constan et al., 1999; Luciene da Silva et al., 1999; Allis and Zhao, 2002) . It has been inferred that the other two THMs (DBCM and TBM) might also be substrates for the same isoform (Constan et al., 1999; Luciene da Silva et al., 1999; Allis and Zhao, 2002) . Therefore, identifying the extent of metabolic inhibition among the four THMs is important for interpreting THMs concentrations measured in human blood. For example, given the same chloroform concentration in water, the corresponding chloroform concentration in blood would be higher in the case where metabolic inhibition occurs (i.e., less chloroform would be metabolized). Accurately characterizing THMs metabolism is also critical when estimating relevant health risk using biomonitoring data because the toxic substances are metabolites of THMs, not the parent compounds.
The present study was undertaken to examine the use of quantitative PBPK modeling to predict the exposures that are associated with specific biomarker levels in blood. Using Monte Carlo sampling, probabilistic information about pharmacokinetics and exposure patterns was included to estimate distributions of THMs concentrations in blood in relation to varying exposures in a diverse population. In addition, the occurrence of inhibition of hepatic metabolism among the THMs was evaluated under the scenarios of household exposure. These studies demonstrated how PBPK modeling can be used as a tool to estimate a population distribution of exposures that could have resulted in particular biomonitoring results. When a toxicity value is available, this tool can also be used to estimate the proportion of the population above levels potentially associated with health risk.
Methods

Model Structure
Among the four THMs, chloroform toxicity and kinetics were best characterized, and more biomonitoring data were available on human exposures to chloroform. Moreover, a PBPK model already existed for chloroform Corley et al., 2000) and was applied in predicting human risk in several studies Delic et al., 2000; Levesque et al., 1994 Levesque et al., , 2000 Levesque et al., , 2002 . Therefore, the structure of the existing PBPK model for chloroform (Corley et al., 2000) was taken as a generic model framework for BDCM, DBCM, and TBM (Figure 1 ). In the PBPK models for these THMs, the values of the physiological parameters remained unchanged from the chloroform model (Phillips et al., 1993; Brown et al., 1997; Clewell et al., 2000) ( Table 1) .
For chemical-specific partition coefficients (Table 2) , some were measured in human tissues (Gargas et al., 1989; Corley et al., 1990; Batterman et al., 2002) and some were measured in rats (Gargas et al., 1989; Corley et al., 1990; Luciene da Silva et al., 1999) . In previous studies with similar volatile organic compounds (VOCs), tissue:air partition coefficients (Corley et al., 2000) , bromodichloromethane, dibromochloromethane, and bromoform.
in rodents and humans were found to be similar (Thomas, 1975) . Therefore, rat tissue:air values were used when human data were not available. The skin:water and skin:air partition coefficients for chloroform were obtained from the literature (Corley et al., 2000) , but such data did not exist for the other THMs. The skin:water partition coefficients of the other THMs were estimated, taking chloroform as a reference compound, using a molecular structure-based algorithm (Poulin and Krishnan, 1996) . The skin:air partition coefficients for these three compounds were calculated as the ratio of their skin:water partition coefficients to the respective Henry's Law constants (i.e., air:water partition coefficients).
The metabolic parameters for BDCM, DBCM, and TBM in human were unavailable, and therefore the rat values (Luciene da Silva et al., 1999) were scaled allometrically for use in the human models (Table 3) . Another chemical-specific parameter obtained from the literature (Corley et al., 2000; WHO, 2000) was the effective skin permeability, which was required to simulate dermal absorption of THMs (Table 3) .
Major exposure scenarios were incorporated into the PBPK models to simulate typical household exposures: (1) ingestion of THMs in tap water, (2) inhalation of THMs in the household air (e.g., THMs volatilized from dishwashing or laundry), and (3) inhalation and dermal absorption while taking showers. The mass transfer of THMs from tap water to air during showering was estimated by a mass transfer model (Weisel et al., 1999) . The current study did not include bathing, which occurs less frequently compared to showering (US EPA 1996) . This study focuses mainly on major exposure events (i.e., showering and drinking water) and merged all other contributing elements (e.g., opening dishwasher; flushing toilet) into the parameter ''chloroform concentrations in ambient air''. Exclusion of these minor exposure scenarios is not expected to significantly alter the results. Moreover, while a more comprehensive exposure regimen may be more realistic, it entails a corresponding increase in model parameters and uncertainty. In this study, the exposure regimen was defined with seven parameters: (1) THMs concentrations in tap water, (2) THMs concentrations in household air, (3) drinking water intake amount per day, (4) mass transfer coefficients for the volatile emissions of THMs during showering, (5) shower duration, (6) shower flow rate, and (7) shower stall dimensions.
Among these seven exposure parameters, drinking water intake amount and shower-related parameters (i.e., duration, flow rate, and stall dimension) were not chemical-specific and their values were obtained from large-scale surveys or reports (Mayer et al., 1999; US EPA, 1996 Levesque et al., 2002) (Table 4 ). THMs concentrations in tap water were measured (in 1984-1987) as part of the US Environmental Protection Agency's (EPA) Total Exposure Assessment Methodology (TEAM) studies (Wallace, 1997) . These water concentrations, representing data collected in three US cities, were used in the individual THMs models.
Chloroform concentrations in household air were measured in the TEAM studies (Wallace, 1997) and these data were used to estimate household air concentrations for the other THMs, which were not measured in the studies. BDCM and DBCM concentrations in air were linearly correlated to chloroform concentrations in air with the ratios estimated from simultaneous measurements in shower air (Kerger et al., 2000) . The estimated ratios (BDCM: chloroform ¼ 0.466; DBCM:chloroform ¼ 0.052) were then multiplied by the measured chloroform concentrations in household air (Wallace, 1997) to calculate BDCM and DBCM concentrations in household air (Table 4) . From the same shower study (Kerger et al., 2000) , TBM concentrations in air were below the detection limit and therefore were assumed to be zero in our modeling analysis (Table 4) . Although the general practice was to set non-detectable values equal to half the detection limit, the practice was not implemented here because the detection limit was not reported (Kerger et al., 2000) . The mass transfer coefficient for chloroform was measured in various shower systems (Little, 1992) (Table 4 ). The mass transfer coefficients for other THMs were calculated from a two-resistance mass-transfer theory model (Little, 1992) using chloroform as a reference chemical (Table 4) . The PBPK models were coded with the graphical simulation tool SIMULINK s , which is part of the MATLAB s technical computing product family (The MathWorks Inc., Natick, MA, USA). MATLAB s m-file scripts describing exposure regimens were used to control the SIMULINK s model for Monte Carlo analysis. All simulations were run on a computer equipped with dual 3.0 GHz Pentium r processors and the Windows XP operating system.
Model Evaluation -Individual Models for Chloroform, BDCM, DBCM, and TBM
Prior to using the PBPK models to estimate environmental exposures consistent with the measured biomonitoring data (i.e., reverse dosimetry), the models were evaluated by simulating tissue concentrations at a given exposure (i.e., forward dosimetry) and comparing the predicted tissue concentrations (e.g., blood concentration) with measured data. Data collected from controlled studies were preferred because they contained the most complete descriptions of how the subjects were exposed and how the tissue concentrations were sampled. Such information allowed a minimal number of assumptions to be made about the exposure conditions.
The evaluation of the chloroform study using showering data has been published elsewhere (Tan et al., 2006) . Results showed that the predicted chloroform concentrations in exhaled breath or blood agreed well with the measured data (Jo et al., 1990; Backer et al., 2000; Levesque et al., 2002) . In the present work, the PBPK models for BDCM, DBCM, and TBM were evaluated by comparing the model simulations with measured concentrations in blood after showering and drinking water (Backer et al., 2000) . Backer et al. (2000) examined 31 volunteers' exposure to THMs through one of the following household activities: (1) showering for 10 min with tap water (n ¼ 11) or (2) drinking 1 L of water during a 10-min period (n ¼ 10). The average tap water concentrations of BDCM and DBCM for showering were 6.2770.686 and 1.2070.092 mg/l, respectively; and for drinking water were 5.5270.204 and 1.0070.027 mg/l, respectively. TBM was not found to be above the detection limit (0.116 mg/l) in any water samples (Backer et al., 2000) , so the TBM concentration in tap water was set to the detection limit. It is possible that the actual TBM concentration in tap water was well below the detection limit, and therefore the present model would provide the most conservative simulations. Blood samples were collected from the volunteers immediately before the exposure, and 10 min (for showering) or 1 h (drinking) following the end of exposure.
Next, the evaluated PBPK models were exercised in conjunction with Monte Carlo analysis to incorporate variability regarding (1) human pharmacokinetics, (2) exposure duration and intensity, (3) temporal profile of exposure events, and (4) timing between sample collection and major exposure events. The incorporation of variability allowed the models to characterize the population distributions of THMs concentrations in blood. These distributions were achieved by randomly sampling model parameters from defined distributions and running the model for a large number of iterations (10,000 iterations in this study). Among the pharmacokinetic parameters (Tables 1-3) , cardiac output, alveolar ventilation rate, partition coefficients, and metabolic parameters were assigned log-normal distributions; tissue volumes, blood flows to tissue, and effective skin permeability coefficient were assigned normal distributions (Delic et al., 2000) . All distributions were truncated at 1.96 times the standard deviation (SD) above and below the mean (B95% of the total distribution) to exclude physiologically implausible values. The distribution of body weight, from age 12 years and up for both genders, was obtained from the National Health and Nutrition Examination Survey (NHANES III) (CDC, 1996) and truncated at the 2.5th and 97.5th percentiles. The same truncating principle was applied to all distributions of exposure parameters (Table 4) . One exception was the distribution of shower stall dimensions, which was truncated at mean71 Â SD, because the sizes of commercially available stalls were fairly uniform.
Along with the pharmacokinetic and exposure parameters, the time of blood sample collection and starting time of exposure (showering, and drinking water) were randomly varied in the Monte Carlo analysis. A uniform distribution was assigned for the time of blood sample collection between 0800 and 2300 hours (personal communication with scientists at the CDC). The distribution of the starting time of showering was obtained from relative percentage data in a published report (Mayer et al., 1999) . There was no information on when or how frequently people drink water; therefore, for demonstration purposes, all individuals were assumed to drink water six times starting at around 0600 hours. The interval between each drinking event was normally distributed with a mean of 3 h and an SD of 0.9 h (coefficient of variance ¼ 30%). As with the other parameters, the distribution was also truncated at mean71.96 Â SD.
Before Monte Carlo analysis, a sensitivity analysis was performed to evaluate the relative significance of the model parameters for predicting BDCM, DBCM, and TBM Measured data (US EPA, 1996). c Measured data (Mayer et al., 1999) . (Table 6 in Wallace, 1997). h No data available; assumed concentrations are below the detection limit. i Assumed normally distributed: the mean and standard deviation (SD) were obtained from 18 reported values (Levesque et al., 2002) . j Assumed normally distributed: the mean was calculated as the average of eight observed values (Little, 1992) , and coefficient of variance (CV) was set to 40%, so that all observed values were contained within the 95% bounds of the distribution. k Assumed normally distributed: the mean was calculated using an estimation method (Little, 1992) with chloroform being a reference chemical, and CV was set to 40% to match the setting for chloroform.
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concentrations in blood. As in the analysis conducted with chloroform (Tan et al., 2006) , a log-normalized sensitivity coefficient (LSC) for each model parameter was calculated to indicate the percent change in model output per unit change (71%) in each parameter (Clewell et al., 1994; Evans et al., 1994) . If the absolute value of an LSC (|LSC|) is near or larger than 1, the specific parameter evaluated is considered to have significant model output sensitivity. In this analysis, an exposure scenario of taking a 15-min shower at 0630 hours, drinking water every 3 h between 0600 and 2100 hours, and having a blood sample taken at 0830 hours, was used to examine the sensitivity of all pharmacokinetic and exposure parameters.
Using Monte Carlo analysis, 10,000 BDCM, DBCM, and TBM concentrations in blood were generated and then compared to the blood data (CDC, 1996) collected between 1988 and 1992. The distribution of water concentrations did not come from the same population that provided the blood data; however, it was obtained from samples collected in a similar era, between 1994 and 1997 (Wallace, 1997) . This comparison was performed to provide a general indication of the PBPK models' ability to support forward dosimetry.
Model Evaluation -Mixture Model Considering Metabolic Inhibition
Another issue that needed to be considered before using the PBPK models in reverse dosimetry was to determine whether metabolic interactions might occur among the four THMs at environmental levels. If metabolic inhibition occurred but was not considered, the model would tend to overestimate THMs concentrations in water at a given blood concentration. Although this phenomenon was not considered likely under the scenarios of household exposure, Monte Carlo implementation of the PBPK models was conducted to examine such likelihood under various exposure conditions.
First, a set of model parameters was randomly selected to run the PBPK models for individual THMs to simulate the household exposure to individual compounds. Next, the same set of parameters sampled in the previous step was used in a PBPK model for the THMs mixture to simulate exposure to all THMs together. This process was repeated 10,000 times to generate 10,000 pairs of THMs concentrations predicted by the individual and mixture models. If the blood concentrations of individual compounds predicted by the individual models were the same as those predicted by the mixture model, then no inhibition would be indicated. However, if the blood concentrations of individual compounds predicted by the individual models were lower than those predicted by the mixture model, metabolic inhibition would be suggested at the water concentrations sampled. In this study, blood concentration was used to assess inhibition. Other measure of metabolism, such as rate of metabolism, simulated in the model could also be used to assess inhibition.
The mixture model had the same structure as the individual THMs models (Figure 1) , except that competitive inhibition in the liver was described using each compound's K m (the concentration at which half the maximal metabolic capacity (V max ) was achieved) as the inhibition constant. For each THMs, the rate equation for metabolism in the presence of the other three THMs was given in Eq. (1):
where RAM 1 is the rate of metabolism of compound 1, V max1 is the maximal rate of metabolism of compound 1, K Mi (i ¼ 1-4) is the Michaelis-Menten constant for compounds 1-4 (i.e., chloroform, BDCM, DBCM, and TBM), and CVL i (i ¼ 1-4) is the venous blood concentration of compounds 1-4 leaving the liver. Separate equations analogous to Eq. (1) were used to calculate the rates of metabolism of compounds 2-4 (RAM 2 , RAM 3 , and RAM 4 ). In the Monte Carlo analyses that evaluated metabolic interactions among the THMs, the correlations among THMs concentrations in water were also considered. To accurately assess these correlations, individual THMs concentrations should be measured from the same water sample. Such data, however, were not reported in the literature; instead, mean THMs concentrations in water were reported (Krasner et al., 1989; Wallace, 1997; Kerger et al., 2000; Egorov et al., 2003; Nuckols et al., 2005) . As these published correlations among mean THMs concentrations in water varied significantly, data that provided the largest regression slopes of mean BDCM (or DBCM or TBM) concentrations versus mean chloroform concentrations in water were chosen (Krasner et al., 1989; Kerger et al., 2000) to estimate BDCM, DBCM, and TBM concentrations in water given a randomly selected chloroform concentration in water. The larger ratios were selected to allow metabolic interactions to be detected, if they occurred. In addition, these ratios were given distributions in the Monte Carlo analyses: normally distributed with means equaled to the regression slopes ( ¼ 0.89, 0.66, and 0.04 for BDCM:chloroform, DBCM:chloroform, and TBM:chloroform, respectively) and variances estimated by Eq. (2):
where the RSS is the residual sum of squares calculated from regressing means of BDCM (or DBCM or TBM) concentrations in water versus means of chloroform concentrations in water, n is the number of paired means of water concentrations, and x i is the mean chloroform concentrations in water. After the THMs concentrations in water were estimated, the THMs concentrations in air were calculated based on the Henry's Law constants from each compound, for example:
BDCM in air BDCM in water : chloroform in air chloroform in water ¼ 0:067 : 0:12 where chloroform air:water ratio was estimated from simultaneously collected data in a shower study (Jo et al., 1990) , and the Henry's Law constants were obtained from US EPA's On-line Tools for Site Assessment Calculation (US EPA, 2005).
Reverse Dosimetry
The relationship between external exposure and tissue doses for each THM was established by simulating the forward dosimetry (external exposure-tissue dose) with the PBPK models. Next, to demonstrate the approach, reverse dosimetry was performed with chloroform biomonitoring data (CDC, 1996) . If adequate data were available, the same technique could be extended to interpret biomonitoring data on the other three THMs. To estimate external exposures consistent with the measured biomonitoring data, the PBPK model for chloroform was used in two alternative reverse dosimetry approaches. Note that the distribution of external exposure predicted by either reverse dosimetry approach is sensitive to the assumptions made regarding exposure patterns in the PBPK models. The first approach uses the Monte Carlo version of the PBPK models to predict the distribution of chloroform concentrations in blood given 1 U of chloroform concentration in water (e.g., 1 mg/l). The output distribution is then inverted to obtain a distribution of an ''exposure conversion factor'' (ECF) in a unit of (mg/l chloroform in water)/(pg/ml chloroform in blood). The distribution of ECFs can then be multiplied by measured biomonitoring data to estimate a distribution of chloroform concentrations in water (mg/l). These concentrations can in turn be multiplied by water intake estimates to predict chloroform intake in mg/kg/day. This approach is more straightforward and easier to implement compared to the second approach below, but is only valid in cases in which tissue dose is linearly related to external exposure level.
The second reverse dosimetry approach is based on a simplified Bayes' formula:
where W is a particular water concentration, B is the blood concentration observed, P(W|B) is the probability of a particular water concentration given the observed blood concentration, P(B|W) is the probability of a specific blood concentration predicted by the PBPK model at a given water concentration and the summation in the denominator is P(B|W) over all the water concentrations used as input to the PBPK model.
In this study, the input water concentrations used in the PBPK model were between 1 ppb chloroform and 10 4 ppb chloroform with a geometric increment of 10 0.2 ppb (e.g., 10 ) and B was divided by the number of iterations of the Monte Carlo run ( ¼ 1000) for a given W. This process was repeated until a matrix was generated with rows being the input water concentration and the columns being the units of blood concentration (P(B|W)). This matrix can then be used to generate a vector of probabilities of water concentrations for each group of blood concentration, P(W|B), using Eq. (3). The vector of probabilities, P(W|B), can be weighted by measured blood concentrations from a population to estimate the distribution of water concentrations to which such population might have been exposed. In this study, the two reverse dosimetry approaches were used to estimate distributions of chloroform concentrations in water given 10,000 hypothetical blood concentrations generated from the percentile data reported in NHANES III (CDC, 1996) .
Results
Model Evaluation -Individual Model for each THM
The model predictions for DBCM concentrations in blood agreed well with the experimental data (Backer et al., 2000) following 10-min showers and drinking of 1-l tap water in 10 min (Figure 2 ). The BDCM model overestimated the mean blood concentrations following showering by a factor of 50% at 10 min after showering, but successfully predicted the mean blood concentrations at 30 min after showering and mean blood concentrations after drinking tap water (Figure 2) . Although overestimating blood concentration in forward dosimetry would lead to underestimation of exposure in reverse dosimetry, having blood samples drawn immediately after showering is unlikely in population-scale biomonitoring studies. As TBM was not found above the detection limit in any blood or water samples (Backer et al., 2000) , the model-predicted TBM concentrations in blood were compared with its detection limit ( ¼ 0.55 ng/l). As observed (Backer et al., 2000) , the predicted TBM concentrations in blood were below the detection limit at 10 min and 30 min (for showering) or 1 h (drinking) following the end of exposure (results not shown). As the actual TBM concentrations in blood were not detectable, how well the model simulated TBM concentrations cannot be appropriately evaluated. In summary, the PBPK models for BDCM and DBCM appear to have satisfactory predictive ability for simulating the relationship between environmental and internal-tissue concentrations.
For all three compounds, only the parameters with |LSC| values larger than 0.5 are shown (Table 5 ). For all compounds analyzed here, shower duration, blood flow to liver, cardiac output and alveolar ventilation rate were among the sensitive parameters. Next, the evaluated PBPK models were exercised in conjunction with Monte Carlo analysis to incorporate variability regarding pharmacokinetics and exposure patterns to conduct forward dosimetry: using distributions defined (Tables 1-4 ) to estimate the distributions of chloroform, BDCM, DBCM, and TBM concentrations in blood. From the Monte Carlo analysis, 10,000 predictions were obtained for each THM (Table 6 ). The predicted distributions of chloroform, BDCM, and DBCM concentrations in blood agreed well with the measured distributions from NHANES III (CDC, 1996) (Table 6 ). No comparison was made for TBM since no TBM data were reported from NHANES III (CDC, 1996) .
Model Evaluation -Mixture Model Considering Metabolic Inhibition
From the Monte Carlo analysis, 10,000 sets of blood concentrations of each individual THM were predicted using both individual models and the mixture model. A percent inhibition was calculated using Eq. (4):
where B individual is the individual model-predicted blood concentration and B mixture is the mixture model-predicted blood concentrations. The median % inhibition was 0.004%, 0.004%, 0.012%, and 0.02% for chloroform, BDCM, DBCM, and TBM, respectively. The maximum % inhibition (i.e., percent inhibitions occurring at the highest predicted exposures) from the 10,000 sets of predictions was 0.8%, 0.5%, 0.8%, and 1.16% for chloroform, BDCM, DBCM, and TBM, respectively. Thus, it is not necessary to consider metabolic interactions under the exposure patterns relevant to the US population.
Reverse Dosimetry
Based on the percentile data of measured chloroform concentrations in blood reported in NHANES III (CDC, 1996) , 10,000 hypothetical blood concentrations were generated for the two reverse dosimetry approaches. From the two approaches, water concentrations possibly associated with the 10,000 hypothetical blood concentrations were estimated and presented as cumulative probability distribu- An individual was assumed to start a 15-min shower at 0630 hours, which resulted in dermal and inhalation exposures to BDCM, DBCM, and TBM. The individual was also assumed to expose to BDCM, DBCM, and TBM from drinking tap water (675 ml/day) at 0600, 0900, 1200, 1500, 1800, and 2100 hours.
tions ( Figure 3 ). Approach 1 (i.e., use of ECFs) resulted in a slightly higher estimate of the distribution of water concentrations. The 50th percentile estimated using Approach 1 was about 50 ppb; whereas the 50th percentile estimated using Approach 2 was about 40 ppb ( Figure 3) . Interestingly, the 50th percentile of the chloroform concentration in water measured in the TEAM study was about 50 ppb ( Table 4 ). Note that the comparison made in the current study was not intended to interpret the NHANES III data. Furthermore, even though both data-sets came from the same era, the population that provided the NHANES III blood concentrations (CDC, 1996) was not the same population from which the water concentrations were determined (Wallace, 1997) . This comparison should be considered an exploratory demonstration of the reverse dosimetry approaches rather than an assessment of the two methods. In addition to predicting the distribution of chloroform concentrations in water (mg/l), the distribution of daily chloroform intake (mg/kg/day) was also estimated using Approach 1 (Figure 4 ).
At the upper percentiles (e.g., 90th), both approaches include estimates of extremely high water concentrations (Figure 3 ). These upper percentile estimates reflect our limited knowledge about the upper limits of variability (i.e., ''true'' individual differences) and uncertainty (i.e., possible errors in estimating the ''true'' values) associated with the model parameters, particularly those related to exposures. The upper tail of the estimated distribution appears to overestimate likely water concentrations, suggesting that this approach would provide a conservative estimate of the distribution of concentrations in water that could be associated with measured biomonitoring data.
Discussion
The traditional risk assessment paradigm is generally based on measures of external exposure. The administered dose, in animal toxicity studies, that is identified as the no-observed- Percentiles of the distributions of chloroform, BDCM, and DBCM concentrations in blood measured by NHANES III (CDC, 1996) are shown for comparison with the predictions.
adverse-effect-level (NOAEL) or lowest-observed-adverseeffect level (LOAEL) is typically incorporated with default uncertainty factors or adjustments to determine a safe exposure level for humans. Biomonitoring data, on the other hand, represents a measure of internal exposure. Therefore, to be put in a risk context, the relationship of human biomonitoring data and human exposures needs to be determined ( Figure 5 ). Using forward dosimetry, pharmacokinetic studies and/or modeling in the experimental animal can be used to support a direct comparison of internal exposures, providing an estimate of the margin of safety.
Alternatively, reverse dosimetry can be performed in human to estimate a distribution of possible external exposures for comparison with an animal-based health standard, such as a RfD or Reference Concentration (RfC).
In the current study, an approach is demonstrated by which biomonitoring data can be interpreted using PBPK modeling and Monte Carlo analysis with relevant exposure data to characterize the population distribution of exposures. This process addresses the influence of variability in interindividual pharmacokinetics and exposures (e.g., shower duration and drinking water ingestion patterns), as well as the influence of timing of biomonitoring data collection with respect to major exposure events. Rather than reconstructing individual exposures from individual biomonitoring data, the main purpose of this study is to demonstrate an approach that integrates biomonitoring data, exposure pattern characterization, PBPK modeling, Monte Carlo analysis, and animal toxicity data to infer human health risk by estimating exposures in a diverse population.
One of the key aspects in the reverse dosimetry approach is to ensure that the PBPK model appropriately simulates the relationship between external and internal measures of exposure. In the current study, human PBPK models for the THMs were developed using scale-up of animal parameters. The ability of these models to perform forward dosimetry was evaluated by comparing model simulations with data from controlled studies (Backer et al., 2000) . The close agreement between the predicted and measured blood concentrations (Figure 2 ) gave confidence in these models. Furthermore, these PBPK models, in conjunction with Monte Carlo analyses, were able to predict blood concentrations similar to those reported in NHANES III (CDC, 1996) Chloroform concentration in water (ppb) Figure 3. Estimated cumulative probability distributions of chloroform concentrations in water (between 1 and 160 ppb) that are consistent with 10,000 hypothetical blood concentrations generated from percentile data reported in NHANES III (CDC, 1996) . The inset shows the full range of the cumulative probability distributions. Approach 1 uses the ''Exposure Conversion Factor'' to estimate the probability distribution of water concentrations. Approach 2 uses a matrix with rows being the input water concentration and the columns being the units of blood concentration to estimate the probability distribution of water concentrations.
Chloroform intake (mg/kg/day) 0 5e-9 5e-8 5e-7 5e-6 5e-5 5e-4 5e-3 5e-2 5e-1 Figure 4 . Estimated probability distribution of chloroform intakes (mg/kg/day) that are consistent with 10,000 hypothetical blood concentrations generated from percentile data reported in NHANES III (CDC, 1996) . Figure 5 . Relationship of human biomonitoring data to animal toxicity data. Human biomonitoring data provides a measure of internal exposure. Traditional risk assessment is based on measures of external exposure. Pharmacokinetic studies in animals can support a direct comparison of internal exposures, providing a margin of safety estimate. Alternatively, reverse dosimetry can be performed to estimate the external exposure in the human to compare with an animal-based health standard.
using the water concentrations in the TEAM study (Wallace, 1997) and exposure scenario information collected on the US population. Another step taken to assure the usefulness of these THMs models was examining the potential metabolic inhibition in THMs mixtures and demonstrating that inhibition is not expected to be important at human exposure levels.
To apply reverse dosimetry in risk assessment, the estimated distribution of exposure can be compared with various regulatory guidelines (e.g., maximum contaminant level; MCL), established using animal toxicity data. Here, several examples are presented using the estimated distribution of chloroform concentrations in water:
(1) Identify the percentage of a population that is exposed to chloroform below a specific point-of-interest, such as the MCL. From the cumulative probability distribution generated using Approach 2, 80% of the population was exposed to 100 ppb or less chloroform in water (Figure 3) , which was the MCL for total THMs at the time the NHANES III study was conducted. (2) Estimate the percentage of a population that had daily chloroform intake above the EPA oral RfD. From the probability distribution generated using Approach 1, 97% of the population had chloroform intake less than 0.01 mg/kg/day. Note that while the RfD could be used in forward dosimetry to predict an equivalent (''safe'') blood concentration, the RfD assumes continuous exposure and the equivalent blood concentration would not be appropriate for a comparison with blood concentrations obtained in the context of intermittent exposure, such as household exposure to chloroform. (3) Compare the 95th percentile of the daily chloroform intake distribution with LOAEL for liver toxicity or LED 10 (95% lower confidence limit of the dose needed to produce an adverse effect in 10% of those exposed to the chemical, relative to control) for liver carcinogenicity in the EPA IRIS (Integrated Risk Information System) database, and calculate the margin of exposure (MOE). The 95th percentile from the distribution of daily chloroform intake was about 9.35 Â 10 À3 mg/kg/day; the LOAEL for chloroform toxicity is 23 mg/kg/day; and the LED 10 for chloroform carcinogenicity is 12.9 mg/kg/day. Thus, the MOE is 2460 when compared to the LOAEL; and 1375 when compared to the LED 10 .
Although this study presents a successful use of biomonitoring data together with modeling tools to estimate population-scale exposure estimates that can be compared with established toxicity values, the interpretability of biomonitoring data of other compounds with less-available pharmacokinetic or exposure scenario information remains a challenge. Biomonitoring data reflect an internal dose associated with external exposures from all potential sources and by all routes. These data can only be interpreted using the reverse dosimetry approach described here when all major exposure sources (natural or synthetic; endogenous or exogenous) are appropriately identified and characterized. Another concern is that biomonitoring data only gives a measure of tissue concentration at the time of sample collection. Depending on the bio-persistence of a compound and the time between exposure and sampling, the measured tissue concentration might reflect recent exposure or exposure accumulated over a longer period of time. Volatile compounds like the THMs are eliminated from the body rapidly after the exposure ceases and hence the biomarker concentrations are highly sensitive to recent exposures. Recent exposure is of less concern for highly persistent compounds like dioxin, but the biomarker concentrations in this case could be affected by physiological changes such as growth or altered body fat content (Clewell et al., 2004) . These considerations need to be explicitly characterized and quantified before it will be possible to interpret biomonitoring data for these compounds.
Our reverse dosimetry approach was developed to interpret population-based biomonitoring data based on probabilistic information regarding pharmacokinetics and exposure patterns in a population. This approach was not intended for reconstructing an individual's exposure from population-based biomarker levels. Our work here developed methodologies necessary to provide a timely and objective interpretation of human biomonitoring data.
